Spyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patients - SGP News | RalliesSpyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patients
S
SGP• Corporate deck highlights BIM-IOL System and trial data
- SpyGlass outlined Phase 3 pivotal trials for its BIM-IOL System, designed to deliver about three years of bimatoprost for OAG/OHT.
- First-in-human data showed 95% of patients off topical IOP therapy at 36 months; mean IOP fell 37% across doses.
- Phase 1/2 data showed 98% off topical therapy at 12 months at the intended 78 mcg dose; mean IOP declined 34%.
- U.S. addressable market estimated at about USD 13 billion; about 1,000,000 glaucoma or OHT patients projected to undergo cataract surgery in 2025.
- Cash, cash equivalents, short-term investments totaled USD 234.2 million as of June 30, 2026.
•
